Report cover image

Global Meningococcal Disease Treatment Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 194 Pages
SKU # APRC20560510

Description

Summary

According to APO Research, The global Meningococcal Disease Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Meningococcal Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Meningococcal Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Meningococcal Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Meningococcal Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Meningococcal Disease Treatment include Walvax Biotechnology Co.,Ltd., Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Beijing Minhai Biological Technology Co.,Ltd., CanSino Biologics Inc., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and Hebei Hejia Pharmaceutical Technology Group Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Meningococcal Disease Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Meningococcal Disease Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Meningococcal Disease Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Disease Treatment revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Meningococcal Disease Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Meningococcal Disease Treatment revenue, projected growth trends, production technology, application and end-user industry.

Meningococcal Disease Treatment Segment by Company

Walvax Biotechnology Co.,Ltd.
Apeloa Pharmaceutical Co.,Ltd.
Novartis
Merck Sharp & Dohme
Beijing Minhai Biological Technology Co.,Ltd.
CanSino Biologics Inc.
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Pfizer
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
GlaxoSmithKline
Chengdu Institute of Biology
Sanofi Pasteur
Meningococcal Disease Treatment Segment by Type

Antibiotics
Vaccines
Meningococcal Disease Treatment Segment by Application

Hospitals
Drugstores
Others
Meningococcal Disease Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Meningococcal Disease Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Meningococcal Disease Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Treatment revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Meningococcal Disease Treatment Market by Type
1.2.1 Global Meningococcal Disease Treatment Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Antibiotics
1.2.3 Vaccines
1.3 Meningococcal Disease Treatment Market by Application
1.3.1 Global Meningococcal Disease Treatment Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Meningococcal Disease Treatment Market Dynamics
2.1 Meningococcal Disease Treatment Industry Trends
2.2 Meningococcal Disease Treatment Industry Drivers
2.3 Meningococcal Disease Treatment Industry Opportunities and Challenges
2.4 Meningococcal Disease Treatment Industry Restraints
3 Global Growth Perspective
3.1 Global Meningococcal Disease Treatment Market Perspective (2020-2031)
3.2 Global Meningococcal Disease Treatment Growth Trends by Region
3.2.1 Global Meningococcal Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Meningococcal Disease Treatment Market Size by Region (2020-2025)
3.2.3 Global Meningococcal Disease Treatment Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Meningococcal Disease Treatment Revenue by Players
4.1.1 Global Meningococcal Disease Treatment Revenue by Players (2020-2025)
4.1.2 Global Meningococcal Disease Treatment Revenue Market Share by Players (2020-2025)
4.1.3 Global Meningococcal Disease Treatment Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Meningococcal Disease Treatment Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Meningococcal Disease Treatment Key Players Headquarters & Area Served
4.4 Global Meningococcal Disease Treatment Players, Product Type & Application
4.5 Global Meningococcal Disease Treatment Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Meningococcal Disease Treatment Market CR5 and HHI
4.6.3 2024 Meningococcal Disease Treatment Tier 1, Tier 2, and Tier 3
5 Meningococcal Disease Treatment Market Size by Type
5.1 Global Meningococcal Disease Treatment Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Meningococcal Disease Treatment Revenue by Type (2020-2031)
5.3 Global Meningococcal Disease Treatment Revenue Market Share by Type (2020-2031)
6 Meningococcal Disease Treatment Market Size by Application
6.1 Global Meningococcal Disease Treatment Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Meningococcal Disease Treatment Revenue by Application (2020-2031)
6.3 Global Meningococcal Disease Treatment Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Walvax Biotechnology Co.,Ltd.
7.1.1 Walvax Biotechnology Co.,Ltd. Comapny Information
7.1.2 Walvax Biotechnology Co.,Ltd. Business Overview
7.1.3 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.1.4 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
7.1.5 Walvax Biotechnology Co.,Ltd. Recent Developments
7.2 Apeloa Pharmaceutical Co.,Ltd.
7.2.1 Apeloa Pharmaceutical Co.,Ltd. Comapny Information
7.2.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
7.2.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.2.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
7.2.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
7.3 Novartis
7.3.1 Novartis Comapny Information
7.3.2 Novartis Business Overview
7.3.3 Novartis Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.3.4 Novartis Meningococcal Disease Treatment Product Portfolio
7.3.5 Novartis Recent Developments
7.4 Merck Sharp & Dohme
7.4.1 Merck Sharp & Dohme Comapny Information
7.4.2 Merck Sharp & Dohme Business Overview
7.4.3 Merck Sharp & Dohme Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.4.4 Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio
7.4.5 Merck Sharp & Dohme Recent Developments
7.5 Beijing Minhai Biological Technology Co.,Ltd.
7.5.1 Beijing Minhai Biological Technology Co.,Ltd. Comapny Information
7.5.2 Beijing Minhai Biological Technology Co.,Ltd. Business Overview
7.5.3 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.5.4 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
7.5.5 Beijing Minhai Biological Technology Co.,Ltd. Recent Developments
7.6 CanSino Biologics Inc.
7.6.1 CanSino Biologics Inc. Comapny Information
7.6.2 CanSino Biologics Inc. Business Overview
7.6.3 CanSino Biologics Inc. Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.6.4 CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio
7.6.5 CanSino Biologics Inc. Recent Developments
7.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
7.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Comapny Information
7.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
7.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio
7.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
7.8 Pfizer
7.8.1 Pfizer Comapny Information
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.8.4 Pfizer Meningococcal Disease Treatment Product Portfolio
7.8.5 Pfizer Recent Developments
7.9 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
7.9.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Comapny Information
7.9.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
7.9.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.9.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio
7.9.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
7.10 GlaxoSmithKline
7.10.1 GlaxoSmithKline Comapny Information
7.10.2 GlaxoSmithKline Business Overview
7.10.3 GlaxoSmithKline Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.10.4 GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio
7.10.5 GlaxoSmithKline Recent Developments
7.11 Chengdu Institute of Biology
7.11.1 Chengdu Institute of Biology Comapny Information
7.11.2 Chengdu Institute of Biology Business Overview
7.11.3 Chengdu Institute of Biology Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.11.4 Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio
7.11.5 Chengdu Institute of Biology Recent Developments
7.12 Sanofi Pasteur
7.12.1 Sanofi Pasteur Comapny Information
7.12.2 Sanofi Pasteur Business Overview
7.12.3 Sanofi Pasteur Meningococcal Disease Treatment Revenue and Gross Margin (2020-2025)
7.12.4 Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio
7.12.5 Sanofi Pasteur Recent Developments
8 North America
8.1 North America Meningococcal Disease Treatment Revenue (2020-2031)
8.2 North America Meningococcal Disease Treatment Revenue by Type (2020-2031)
8.2.1 North America Meningococcal Disease Treatment Revenue by Type (2020-2025)
8.2.2 North America Meningococcal Disease Treatment Revenue by Type (2026-2031)
8.3 North America Meningococcal Disease Treatment Revenue Share by Type (2020-2031)
8.4 North America Meningococcal Disease Treatment Revenue by Application (2020-2031)
8.4.1 North America Meningococcal Disease Treatment Revenue by Application (2020-2025)
8.4.2 North America Meningococcal Disease Treatment Revenue by Application (2026-2031)
8.5 North America Meningococcal Disease Treatment Revenue Share by Application (2020-2031)
8.6 North America Meningococcal Disease Treatment Revenue by Country
8.6.1 North America Meningococcal Disease Treatment Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Meningococcal Disease Treatment Revenue by Country (2020-2025)
8.6.3 North America Meningococcal Disease Treatment Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Meningococcal Disease Treatment Revenue (2020-2031)
9.2 Europe Meningococcal Disease Treatment Revenue by Type (2020-2031)
9.2.1 Europe Meningococcal Disease Treatment Revenue by Type (2020-2025)
9.2.2 Europe Meningococcal Disease Treatment Revenue by Type (2026-2031)
9.3 Europe Meningococcal Disease Treatment Revenue Share by Type (2020-2031)
9.4 Europe Meningococcal Disease Treatment Revenue by Application (2020-2031)
9.4.1 Europe Meningococcal Disease Treatment Revenue by Application (2020-2025)
9.4.2 Europe Meningococcal Disease Treatment Revenue by Application (2026-2031)
9.5 Europe Meningococcal Disease Treatment Revenue Share by Application (2020-2031)
9.6 Europe Meningococcal Disease Treatment Revenue by Country
9.6.1 Europe Meningococcal Disease Treatment Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Meningococcal Disease Treatment Revenue by Country (2020-2025)
9.6.3 Europe Meningococcal Disease Treatment Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Meningococcal Disease Treatment Revenue (2020-2031)
10.2 China Meningococcal Disease Treatment Revenue by Type (2020-2031)
10.2.1 China Meningococcal Disease Treatment Revenue by Type (2020-2025)
10.2.2 China Meningococcal Disease Treatment Revenue by Type (2026-2031)
10.3 China Meningococcal Disease Treatment Revenue Share by Type (2020-2031)
10.4 China Meningococcal Disease Treatment Revenue by Application (2020-2031)
10.4.1 China Meningococcal Disease Treatment Revenue by Application (2020-2025)
10.4.2 China Meningococcal Disease Treatment Revenue by Application (2026-2031)
10.5 China Meningococcal Disease Treatment Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Meningococcal Disease Treatment Revenue (2020-2031)
11.2 Asia Meningococcal Disease Treatment Revenue by Type (2020-2031)
11.2.1 Asia Meningococcal Disease Treatment Revenue by Type (2020-2025)
11.2.2 Asia Meningococcal Disease Treatment Revenue by Type (2026-2031)
11.3 Asia Meningococcal Disease Treatment Revenue Share by Type (2020-2031)
11.4 Asia Meningococcal Disease Treatment Revenue by Application (2020-2031)
11.4.1 Asia Meningococcal Disease Treatment Revenue by Application (2020-2025)
11.4.2 Asia Meningococcal Disease Treatment Revenue by Application (2026-2031)
11.5 Asia Meningococcal Disease Treatment Revenue Share by Application (2020-2031)
11.6 Asia Meningococcal Disease Treatment Revenue by Country
11.6.1 Asia Meningococcal Disease Treatment Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Meningococcal Disease Treatment Revenue by Country (2020-2025)
11.6.3 Asia Meningococcal Disease Treatment Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Meningococcal Disease Treatment Revenue (2020-2031)
12.2 SAMEA Meningococcal Disease Treatment Revenue by Type (2020-2031)
12.2.1 SAMEA Meningococcal Disease Treatment Revenue by Type (2020-2025)
12.2.2 SAMEA Meningococcal Disease Treatment Revenue by Type (2026-2031)
12.3 SAMEA Meningococcal Disease Treatment Revenue Share by Type (2020-2031)
12.4 SAMEA Meningococcal Disease Treatment Revenue by Application (2020-2031)
12.4.1 SAMEA Meningococcal Disease Treatment Revenue by Application (2020-2025)
12.4.2 SAMEA Meningococcal Disease Treatment Revenue by Application (2026-2031)
12.5 SAMEA Meningococcal Disease Treatment Revenue Share by Application (2020-2031)
12.6 SAMEA Meningococcal Disease Treatment Revenue by Country
12.6.1 SAMEA Meningococcal Disease Treatment Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Meningococcal Disease Treatment Revenue by Country (2020-2025)
12.6.3 SAMEA Meningococcal Disease Treatment Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.